University of Nebraska

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Nebraska sits in the top decile of US sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count).

407 total trials 51 currently recruiting 261 completed early-phase tilt top decile by trial count

University of Nebraska: 407 sponsored US clinical trials, 51 recruiting.

University of Nebraska sponsors 407 registered US clinical trials on ClinicalTrials.gov, 51 of them currently recruiting, and 261 completed. 31 of these trials are in Phase 3-4 (later-stage) and 109 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Peripheral Arterial Disease, with 7 trials.

Top-decile sponsor footprint

University of Nebraska ranks in the top decile of sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 36/100

261 of 332 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

407 total, page 7 of 9

COMPLETED

Study to Test the Usefulness of Magnetoencephalography (MEG) Imaging of Cognition in Children and Adolescents

NCT00924300
TERMINATED Phase 4

Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation

NCT00936663
COMPLETED

Economic Outcomes of Enteral and Parenteral Proton Pump Inhibitor (PPI) Use in the Intensive Care Unit (ICU)

NCT00919152
COMPLETED NA

Reducing Risk in Cardiac Rehabilitation: Partners Together in Health (PaTH) Intervention Study

NCT00926848
COMPLETED

Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections

NCT00870623
COMPLETED

Prevalence of Sleep Apnea in Patients Presenting for Hip or Knee Replacement Surgery

NCT00874822
COMPLETED Phase 2

Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis

NCT00826020
TERMINATED Early Phase 1

Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers

NCT00882193
COMPLETED Phase 1

Regadenoson R-T Perfusion Imaging Trial

NCT00837369
COMPLETED

Duration and Direct Cost of Behavioral Health Concerns in Pediatric Primary Care

NCT00922922
COMPLETED

Real Time Myocardial Contrast Echocardiography and Dobutamine Stress Perfusion Magnetic Resonance Imaging

NCT00861848
TERMINATED

Evaluation of Vancomycin Treatment of Infections Due to Staphylococcus Aureus

NCT00862862
COMPLETED NA

Wii-fit for Activity, Balance and Gait in Assisted Living

NCT01000038
TERMINATED NA

Heading Off Peripheral Neuropathy With Exercise

NCT00869804
COMPLETED

Study of Urine Samples From Women With Newly Diagnosed Breast Cancer Enrolled on Clinical Trial UNMC-08105

NCT00959244
COMPLETED Phase 1

Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer

NCT00856037
COMPLETED

Arteriovenous Fistula Tissue Bank for Pre- and Post-Fistula Placement Specimens

NCT00836862
COMPLETED

Vascular Changes Following Forearm Loop Arteriovenous Graft Placement

NCT00836563
COMPLETED

Risk and Protective Factors for Rural Methamphetamine Dependence

NCT00882037
COMPLETED

Utility of Bedside Ultrasound in the Prediction of Difficult Airway

NCT00799357
TERMINATED

Effect of Panretinal Photocoagulation on Optic Nerve Head Topography

NCT00767884
COMPLETED NA

Vitamin D Replacement After Kidney Transplant

NCT00748618
COMPLETED Phase 4

Long Acting Stimulant Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Young Children

NCT00754208
COMPLETED

Imaging Modalities in Detection of Coronary Artery Disease in End-stage Renal Disease Patients

NCT00726921
COMPLETED

Airway Macrophages and Sputum Milieu in Adult Subjects With Airflow Obstruction

NCT00871637
TERMINATED Early Phase 1

Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

NCT00736450
COMPLETED

Relationship Between Physical Activity and Stem Cells in Older Adults

NCT00690183
COMPLETED

Assess Vitamin D Levels in Those With & Without Thyroid Cancer

NCT00719615
TERMINATED Phase 2

Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

NCT00679029
COMPLETED NA

Emergency Department Interventions to Improve Blood Pressure Follow-up

NCT00798551
COMPLETED

Followup of Glenoid Fix Utilizing Auto Bone Graft in Shoulder Replacement

NCT00670852
COMPLETED NA

Distribution of Topical Nasal Medication Within the Nasal Cavity and Sinuses by Radiographic Comparison

NCT00626366
COMPLETED

Specialized Substance Abuse Supervision (SSAS) Versus Non-SSAS Recidivism Rates Among Nebraska Felony Drug Offenders

NCT00690352
COMPLETED

Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin

NCT00577798
COMPLETED Phase 2

Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer

NCT00602797
COMPLETED Phase 4

Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment

NCT00536172
COMPLETED NA

Stereotactic Radiation Therapy in Treating Patients With Advanced Liver Cancer

NCT00607828
COMPLETED Phase 1

Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer

NCT01068327
COMPLETED

Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma

NCT00617799
TERMINATED Early Phase 1

Two-Layer Method Preservation and Resuscitation of the Cadaveric Pancreas Before Transplantation

NCT00592280
COMPLETED Phase 1

Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00550615
COMPLETED NA

Bupropion in the Treatment of Methamphetamine Dependence

NCT00572234
TERMINATED Phase 1

Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes

NCT00503880
COMPLETED

Vascular Risk Progression in Normal and Diabetic Control Subjects.

NCT00579228
TERMINATED Phase 2

Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer

NCT00496756
COMPLETED

Quality End-of-Life Care in Nursing Homes

NCT00616473
COMPLETED

Gene-Environment Interactions in Rheumatoid Arthritis Autoimmunity Disease Severity

NCT00594451
COMPLETED

Breast Cancer Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer

NCT00666731
TERMINATED

Evaluation of Airway Gene Expression in COPD and Controlled Populations

NCT00571792
COMPLETED Phase 1

Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors

NCT00483366
← Previous Page 7 of 9 Next →

Phase Distribution

PhaseTrial count
Phase 1 57
Phase 2 52
Phase 3 10
Phase 4 21

Therapeutic Areas

Peripheral Arterial Disease 7
Lymphoma 6
Breast Cancer 5
Rheumatoid Arthritis 5
Peripheral Artery Disease 3
Multiple Myeloma 3
Healthy 3
Sleep Fragmentation 2
Graft-versus-host Disease (GVHD) 2
Parkinson's Disease 2

What is open in the University of Nebraska pipeline

51 recruiting of 407 indexed (13% open); 261 completed (64%).

Phase mix: 31 late (III/IV) vs 109 early (I/II) (early-phase heavy).

Top condition: Peripheral Arterial Disease (7 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Nebraska: open-pipeline peers nationwide

Peers matched on 407 registered trials and 13% open enrollment, not the therapeutic-area sidebar.

University of Nebraska sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400500 10%15%20%25% Total trials Recruiting share University of NebraskaCase Comprehensive Cancer CenterTakedaUniversity of Kansas Medical CenterSt. Jude Children's Research HospitalAddario Lung Cancer Medical InstituteAmerican UniversityAnnexonAnsun Biopharma
University of Nebraska sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Nebraska sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 407 trials (± recruiting share)

Sponsors near 13% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this University of Nebraska page

407 registered trials is a research-attention snapshot, not an endorsement of University of Nebraska or any single study.

  • 51 of University of Nebraska's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Peripheral Arterial Disease is the condition University of Nebraska studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Peripheral Arterial Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Nebraska pipeline card: 407 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.